Checking Blood Sugar Tracking in Patients With Heart Pumps
Compares a glucose sensor with the A1c test in people with diabetes and heart pumps.
Plain-language title generated from the registry record
Registry title: A Study of Glycemic Control in Left Ventricular Assist
Key facts
- Where
- Rochester, United StatesSee the site
Where in United States
- Mayo Clinic in RochesterRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT05933161
- Record updated
- 8 May 2026
- Original description
The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.Read full original descriptionShow less
GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)
The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.
Inclusion: Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010; Diagnosis of type II diabetes mellitus; Any antihyperglycemic regimen; Greater than 3 months out from LVAD implantation; Capable of utilizing smartphone device for LibreLink app for uploading glycemic data; Patients may be enrolled who have preexisting CGM in place.
Exclusion: Type I diabetics; Unable to return at 3 month evaluation; Unwillingness to participate.